The National Research Council of Canada is joining forces with the University of Saskatchewan’s Vaccine and Infections Disease Organization-International Vaccine Centre to speed up development and production of a candidate COVID-19 antigen. That antigen is a key component for a vaccine. VIDO-InterVac has identified a recombinant protein antigen that will serve as a primary part of a vaccine candidate. The antigen has been produced at laboratory scale. The NRC has developed cells with specific properties that would make it useful in the production of medicines such as VIDO’s candidate antigen.